Benzyl Benzoate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Benzyl Benzoate: From Ectoparasite Treatment to Pharyngitis
One-Sentence Summary
Benzyl benzoate is marketed in Singapore as a 25% topical emulsion. The data compiled for this report do not list an approved indication, but the drug is generally known as a scabicide and pediculicide. The TxGNN model predicts it may be effective for pharyngitis, but there are 0 clinical trials and 0 publications supporting this prediction, so it rests on a computational score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration data (generally known as a topical scabicide/pediculicide) |
| Predicted New Indication | Pharyngitis |
| TxGNN Prediction Score | 88.66% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Benzyl benzoate is a topical agent known to act on ectoparasites such as scabies mites and lice, probably through neurotoxic effects on the parasite. No plausible link to pharyngeal infection or inflammation has been established.
The predicted indication is therefore not supported by a known pharmacological rationale. The TxGNN score of 0.887 is a computational output only. Other top-ranked predictions include nasal cavity disease, vaginitis, acute laryngopharyngitis, vulvitis, bacterial vaginosis, vaginal discharge, vulvovaginitis, leukoplakia of vagina and vulvovaginal candidiasis. None of them has clinical or mechanistic support in the data compiled for this report. Benzyl benzoate is also a known skin and mucosal irritant and potential contact sensitizer, which is a concern for mucosal sites such as the throat, nose and genital tract.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for pharyngitis.
For the third-ranked prediction (vaginitis), one preclinical paper was retrieved: 40190812 (2025, Drug Des Devel Ther), a mouse study of a progesterone microneedle patch for preterm birth prevention. Benzyl benzoate is probably mentioned only as a formulation component, so this is not evidence of efficacy in vaginitis.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN06735P | BENZYL BENZOATE APPLICATION BP 25% w/v (ICM Pharma Pte. Ltd.) | Emulsion | Not stated in the registration data |
Safety Considerations
- Known irritation potential: Benzyl benzoate is a known skin and mucosal irritant and a potential contact sensitizer, so use on inflamed or mucosal tissue (throat, nasal cavity, vulvovaginal area) raises safety concerns.
No interaction records were found in the data compiled for this report. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for pharyngitis has no clinical trials, no literature and no mechanistic basis. The evidence level is L5, and the irritant nature of the drug argues against use on mucosal sites without further work. The product is registered in Singapore only as a topical emulsion, and its formulation is not suited to the predicted site.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank)
- Package insert warnings and contraindications from the HSA, which are currently missing and block safety screening
- Preclinical or in vitro evidence of activity against pathogens or inflammation relevant to pharyngitis
- Route and formulation compatibility assessment for any pharyngeal use
- Mucosal tolerability and sensitization assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.